Adverse event totals12

The totals the trial posted for each group.

1 to 12 of 12

Total	Group	Affected	At risk
Total, all-cause mortality	Stage 1: Pola-R-GemOx	9	15
Total, all-cause mortality	Stage 2: R-GemOx	83	125
Total, all-cause mortality	Stage 2: Pola-R-GemOx	68	128
Total, all-cause mortality	Pola-R-GemOx - Pooled	77	143
Total, other adverse events	Stage 1: Pola-R-GemOx	14	15
Total, other adverse events	Stage 2: R-GemOx	111	125
Total, other adverse events	Stage 2: Pola-R-GemOx	119	128
Total, other adverse events	Pola-R-GemOx - Pooled	133	143
Total, serious adverse events	Stage 1: Pola-R-GemOx	2	15
Total, serious adverse events	Stage 2: R-GemOx	39	125
Total, serious adverse events	Stage 2: Pola-R-GemOx	49	128
Total, serious adverse events	Pola-R-GemOx - Pooled	51	143

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04182204/event-totals